TITLE

Clinical Trials in Surgical Oncology–Introduction

AUTHOR(S)
Jatoi, Ismail
PUB. DATE
July 2006
SOURCE
World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the importance of clinical trials in managing cancer and cancer patients. Clinical trials as well as patient participation in trials conducted, has contributed in stabilizing mortality rates of cancer patients and has brought improvement in managing the disease. Development in cancer treatment will be enhance upon application and implementation of new and effective clinical trials.
ACCESSION #
21553386

 

Related Articles

  • Clinical Trial Results Applied to Management of the Individual Cancer Patient. Jatoi, Ismail; Proschan, Michael A. // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1184 

    The application of clinical trial results to the management of the individual cancer patient is not always straightforward. The results of a clinical trial indicate the “average” effect of an intervention, often expressed in terms of an absolute risk reduction, which is an estimate...

  • Efficacy of NiTi Hand CACâ„¢ 30 for jejunojejunostomy in gastric cancer surgery: results from a multicenter prospective randomized trial. Hoon Hur; Hyung Ho Kim; Woo Jin Hyung; Gyu Seok Cho; Wook Kim; Seung Wan Ryo; Sang-Uk Han // Gastric Cancer;Jun2011, Vol. 14 Issue 2, p124 

    Background: Although a novel technique for the performance of intestinal sutureless anastomosis using a compression device has recently been investigated, it has not yet received widespread acceptance. We performed a multicenter prospective randomized trial in order to determine the clinical...

  • Impact of Cultural and Linguistic Factors on Symptom Reporting by Patients With Cancer. Wang, Xin Shelley; Cleeland, Charles S.; Mendoza, Tito R.; Young Ho Yun; Ying Wang; Okuyama, Toru; Johnson, Valen E. // JNCI: Journal of the National Cancer Institute;5/19/2010, Vol. 102 Issue 10, p732 

    Background: Patient reporting of the severity and impact of symptoms is an essential component of cancer symptom management and cancer treatment clinical trials. In multinational clinical trials, cultural and linguistic variations in patient-reported outcomes instruments could confound the...

  • Satraplatin.  // Pharmaceutical Representative;Apr2009, Vol. 39 Issue 4, p9 

    The article presents the clinical trial on the effectiveness of Satraplatin. A Phase III SPARC trial shows that the said medication has the ability to ameliorate the survivability of patients who are succumbed with prostate cancer. In addition, this drug can be administered after administering...

  • The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Phillips, Tiffany M.; Mcbride, William H.; Pajonk, Frank // JNCI: Journal of the National Cancer Institute;12/20/2006, Vol. 98 Issue 24, p1777 

    Background: If cancer arises and is maintained by a small population of cancer-initiating cells within every tumor, understanding how these cells react to cancer treatment will facilitate improvement of cancer treatment in the future. Cancer-initiating cells can now be prospectively isolated...

  • Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials Djulbegovic, Benjamin; Kumar, Ambuj; Miladinovic, Branko; Reljic, Tea; Galeb, Sanja; Mhaskar, Asmita; Mhaskar, Rahul; Hozo, Iztok; Tu, Dongsheng; Stanton, Heather A.; Booth, Christopher M.; Meyer, Ralph M. // PLoS Clinical Trials;Mar2013, Vol. 8 Issue 3, p1 

    Objective: To assess if commercially sponsored trials are associated with higher success rates than publicly-sponsored trials. Study Design and Settings: We undertook a systematic review of all consecutive, published and unpublished phase III cancer randomized controlled trials (RCTs)...

  • Sorafenib in Advanced Renal Cancer: A Viewpoint by Michael Staehler.  // Drugs;2007, Vol. 67 Issue 3, p484 

    The author reflects on the use of sorafenib drug for treatment of advanced renal cancer. According to the author, sorafenib was introduced as an oral multikinase inhibitor of the angiogenic pathways. The author has noted that in a clinical trials of sorafenib, the toxicity profile was...

  • Sorafenib in Advanced Renal Cancer: A Viewpoint by Brian I. Rini.  // Drugs;2007, Vol. 67 Issue 3, p484 

    The author reflects on the use of sorafenib drug for treatment of renal cancer. According to the author, two large, randomized clinical trials have shown that sorafenib agent prolongs progression-free survival in metastatic renal cancer patients compared with placebo. The author has stressed...

  • Meta-analysis of clodronate and breast cancer survival. Ha, T. C.; Li, H. // British Journal of Cancer;6/18/2007, Vol. 96 Issue 12, p1796 

    Clinical trials have reported conflicting results on whether oral clodronate therapy improves survival in breast cancer patients. This study was undertaken to evaluate further the effect of oral clodronate therapy on overall survival, bone metastasis-free survival and nonskeletal metastasis-free...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics